CLL

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's challenges.

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

Waiting for results of a CT scan after a cancer diagnosis is agonizing, as I anxiously await news on whether my disease has returned.

When I recognize my frustration and dissapointment with the test results for my chronic lymphocytic leukemia, I find comfort in listening to music.

As I prepare for treatment of my chronic lymphocytic leukemia, I reflect on the challenges of aging and side effects while staying focused on living fully.

Throughout the year, CURE® contributors shared personal stories and reflections highlighting the multifaceted nature of cancer care.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.

I haven’t been too happy with my blood work with CLL, but I try to enjoy what I can — including apples during fall.

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Patients with treatment-naive CLL/SLL experienced long-term improved efficacy when treated with Brukinsa compared with bendamustine plus Rituxan.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

As a patient with chronic lymphocytic leukemia, I recently gleaned three new insights from my oncologist and phlebotomist.

Two dear friends have introduced helpful items to me, such as a chemo jacket since I became cold in the treatment room.

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

Patients with relapsed or refractory CLL or SLL may benefit from receiving Brukinsa instead of Imbruvica, as Brukinsa demonstrated superior effectiveness.

I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.

From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic lymphocytic leukemia.

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

As I visit the cancer center for chemotherapy to treat my CLL, I can’t help but take note of how different cancer may look in each person.

During chemotherapy for my chronic lymphocytic leukemia, I try my best to appreciate the positive aspects of life, like flowers and friends.

During my chemotherapy treatments for chronic lymphocytic leukemia, I had a supportive group of people surrounding me.

It was beneficial for both myself and my loved ones when I gave a concrete answer to the question of “how can I help?”

A novel Calquence regimen demonstrated improved outcomes in certain patients with chronic lymphocytic leukemia.

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.

Being in nature calms me, and I realized that research backs up what I’ve been experiencing.

My oncologist said that having a supportive community during cancer is just as important as treatment and I could not agree more — it makes me thankful.